Advanced

Sperm DNA integrity in cancer patients: the effect of disease and treatment.

Ståhl, Olof LU ; Eberhard, Jakob LU ; Cavallin-Ståhl, Eva LU ; Jepson, K; Friberg, Britt LU ; Tingsmark, C; Spanò, M and Giwercman, Aleksander LU (2009) In International journal of andrology 32. p.695-703
Abstract
Summary As oncological treatment might impair the patients' fertility, male cancer patients are offered to cryopreserve semen prior to treatment. Impaired sperm DNA quality is associated with reduced fertility, and in case of assisted reproduction, sperm DNA integrity may have an impact on choice of method. Therefore, we have assessed sperm DNA integrity in cancer patients, comparing pre- and post-treatment quality. Sperm DNA integrity was investigated in cryopreserved semen from 121 cancer patients, the predominating diagnoses were germ cell cancer (GCC) and Hodgkin's lymphoma (HL). Post-treatment samples, with a median follow-up of 3 years, were analysed for 58 of the men, allowing a pre- and post-treatment analysis on an individual... (More)
Summary As oncological treatment might impair the patients' fertility, male cancer patients are offered to cryopreserve semen prior to treatment. Impaired sperm DNA quality is associated with reduced fertility, and in case of assisted reproduction, sperm DNA integrity may have an impact on choice of method. Therefore, we have assessed sperm DNA integrity in cancer patients, comparing pre- and post-treatment quality. Sperm DNA integrity was investigated in cryopreserved semen from 121 cancer patients, the predominating diagnoses were germ cell cancer (GCC) and Hodgkin's lymphoma (HL). Post-treatment samples, with a median follow-up of 3 years, were analysed for 58 of the men, allowing a pre- and post-treatment analysis on an individual basis. Sperm DNA integrity was assessed using the Sperm Chromatin Structure Assay and expressed here as the DNA Fragmentation Index (DFI%). One hundred and thirty-seven fertile men served as controls. Before treatment, GCC (n = 84) and HL (n = 18) patients had higher DFI% than controls (n = 143) with a mean difference of 7.7 (95% CI 3.2-8.8) and 7.0 (95% CI 2-12), respectively. The same trend was observed for other cancer diagnoses, but without reaching statistical significance (mean difference 3.6, 95% CI -1.2 to 8.4). No increase was seen in DFI% comparing pre- and post-treatment semen, regardless of treatment modality. A moderate elevation of DFI% was observed in cryopreserved semen from cancer patients. Oncological treatment, generally, did not induce any increase in DFI. These findings should be considered when discussing the utilization of pre-treatment cryopreserved semen vs. post-treatment fresh sperm in cancer patients undergoing assisted reproduction. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
International journal of andrology
volume
32
pages
695 - 703
publisher
Wiley-Blackwell
external identifiers
  • WOS:000271521500013
  • PMID:19178596
  • Scopus:70449358522
ISSN
1365-2605
DOI
10.1111/j.1365-2605.2008.00933.x
language
English
LU publication?
yes
id
fc687dfd-8935-4976-bd4a-fcc8199492be (old id 1289185)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/19178596?dopt=Abstract
date added to LUP
2009-02-04 12:29:59
date last changed
2016-11-23 18:33:48
@misc{fc687dfd-8935-4976-bd4a-fcc8199492be,
  abstract     = {Summary As oncological treatment might impair the patients' fertility, male cancer patients are offered to cryopreserve semen prior to treatment. Impaired sperm DNA quality is associated with reduced fertility, and in case of assisted reproduction, sperm DNA integrity may have an impact on choice of method. Therefore, we have assessed sperm DNA integrity in cancer patients, comparing pre- and post-treatment quality. Sperm DNA integrity was investigated in cryopreserved semen from 121 cancer patients, the predominating diagnoses were germ cell cancer (GCC) and Hodgkin's lymphoma (HL). Post-treatment samples, with a median follow-up of 3 years, were analysed for 58 of the men, allowing a pre- and post-treatment analysis on an individual basis. Sperm DNA integrity was assessed using the Sperm Chromatin Structure Assay and expressed here as the DNA Fragmentation Index (DFI%). One hundred and thirty-seven fertile men served as controls. Before treatment, GCC (n = 84) and HL (n = 18) patients had higher DFI% than controls (n = 143) with a mean difference of 7.7 (95% CI 3.2-8.8) and 7.0 (95% CI 2-12), respectively. The same trend was observed for other cancer diagnoses, but without reaching statistical significance (mean difference 3.6, 95% CI -1.2 to 8.4). No increase was seen in DFI% comparing pre- and post-treatment semen, regardless of treatment modality. A moderate elevation of DFI% was observed in cryopreserved semen from cancer patients. Oncological treatment, generally, did not induce any increase in DFI. These findings should be considered when discussing the utilization of pre-treatment cryopreserved semen vs. post-treatment fresh sperm in cancer patients undergoing assisted reproduction.},
  author       = {Ståhl, Olof and Eberhard, Jakob and Cavallin-Ståhl, Eva and Jepson, K and Friberg, Britt and Tingsmark, C and Spanò, M and Giwercman, Aleksander},
  issn         = {1365-2605},
  language     = {eng},
  pages        = {695--703},
  publisher    = {ARRAY(0x99c3438)},
  series       = {International journal of andrology},
  title        = {Sperm DNA integrity in cancer patients: the effect of disease and treatment.},
  url          = {http://dx.doi.org/10.1111/j.1365-2605.2008.00933.x},
  volume       = {32},
  year         = {2009},
}